AndreaBozzo/ceres-open-data-index huggingface dataset:
NNDSS - TABLE 1HH. Syphilis, Congenital to Syphilis, Primary and Secondary

NNDSS - TABLE 1HH. Syphilis, Congenital to Syphilis, Primary and Secondary – 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
NNDSS - TABLE 1HH. Streptococcal toxic shock syndrome to Syphilis, Primary and Secondary

NNDSS - TABLE 1HH. Streptococcal toxic shock syndrome to Syphilis, Primary and Secondary - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. † Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
NNDSS - Table 1H.  Cholera to Coccidioidomycosis

NNDSS - Table 1H. Cholera to Coccidioidomycosis - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Data from California published in week 29 for years 2019 and 2020 were incomplete when originally published on July 24, 2020. On August 4, 2020, incomplete case counts were replaced with a "U" indicating case counts are not available for specified time period. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
NNDSS - Table 1H. Cholera to Coccidioidomycosis

NNDSS - Table 1H. Cholera to Coccidioidomycosis - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notes: • These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. • Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html. • The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance. Footnotes: *Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks.
NNDSS - Table 1H. Cholera to Coccidioidomycosis

NNDSS - Table 1H. Cholera to Coccidioidomycosis - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. Notice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island. Note: This table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. Footnotes: U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data. -: No reported cases — The reporting jurisdiction did not submit any cases to CDC. N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction. NN: Not nationally notifiable — This condition was not designated as being nationally notifiable. NP: Nationally notifiable but not published. NC: Not calculated — There is insufficient data available to support the calculation of this statistic. Cum: Cumulative year-to-date counts. Max: Maximum — Maximum case count during the previous 52 weeks. * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. †Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
HHS Unaccompanied Children Program

This data is no longer being updated. New data is being tracked at https://healthdata.gov/National/HHS-Unaccompanied-Children-Program/ehpz-xc9n This data represents unaccompanied children who are taken into custody by Customs and Border Protection brought to a facility and processed for transfer to the Department of Health and Human Services (HHS) as required by law. HHS holds the child for testing and quarantine, and shelters the child until the child is placed with a sponsor here in the United States.
Adult Tobacco Consumption In The U.S., 2000-Present

2000 to Present. Adult Tobacco Consumption in the U.S. This dataset highlights critical trends in adult total and per capita consumption of both combustible (cigarettes, little cigars, small cigars, pipe tobacco, roll-your-own tobacco) tobacco products and smokeless (chewing tobacco and snuff) tobacco from 2000 to present. To view the CDC MMWR report, please visit https://www.cdc.gov/mmwr/volumes/65/wr/mm6548a1.htm.
2020 Final Assisted Reproductive Technology (ART) Services and Profiles

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Services and Profiles dataset provides an overview of clinic services, the clinic’s contact information, location, the medical director’s name, and summary statistics.
2020 Final Assisted Reproductive Technology (ART) Success Rates

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Success Rates dataset contains success rates for ART cycles started during the year indicated. Since ART success depends on whether patients are using their own eggs or donor eggs, success rates are included separately for these two groups. Success rates for patients using their own eggs are shown per intended retrieval, per actual retrieval, and per transfer. These success rates are reported as cumulative success rates, which take into account transfers that occur within 1 year after an egg retrieval. Since ART success depends on whether patients are using ART for the first time or had prior ART cycles, users can examine success rates for all “Patients using their own eggs” or for “Patients with no prior ART using their own eggs.” For new patients using ART for the first time, the success rates are also shown after 1, 2, or all intended egg retrievals during the reporting year. In addition, the average number of transfers per intended retrieval and the average number of intended retrievals per live-birth delivery are shown. Success rates for ART cycles that involve the transfer of embryos created from donor eggs or donated embryos are shown and are not cumulative. They are based on donor cycles started in the year indicated that had embryo transfers, regardless of when the donor eggs were retrieved. Success rates in this section are not presented by patient age group because previous data show that an intended parent’s age does not substantially affect success when using donor eggs or donated embryos. The success rates are presented by types of embryos and eggs used in the transfer. This dataset excludes cycles that were considered research—that is, cycles performed to evaluate new procedures.
500 Cities: City-level Data (GIS Friendly Format), 2017 release

2015, 2014. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census city-level data in GIS-friendly format can be joined with city spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-City-Boundaries/n44h-hy2j) in a geographic information system (GIS) to produce maps of 27 measures at the city-level. Because some questions are only asked every other year in the BRFSS, there are 7 measures in this 2017 release from the 2014 BRFSS that were the same as the 2016 release.
2020 Final Assisted Reproductive Technology (ART) Patient and Cycle Characteristics

ART data are made available as part of the National ART Surveillance System (NASS) that collects success rates, services, profiles and annual summary data from fertility clinics across the U.S. There are four datasets available: ART Services and Profiles, ART Patient and Cycle Characteristics, ART Success Rates, and ART Summary. All four datasets may be linked by “ClinicID.” ClinicID is a unique identifier for each clinic that reported cycles. The Patient and Cycle Characteristics dataset summarizes the types of ART services performed and the kinds of patients who received ART procedures in a specific clinic. Please note patient characteristics are presented per cycle rather than per patient. As a result, patients who had more than one ART cycle within the reporting year are represented more than once.
1998-2024 Serotype Data for Invasive Pneumococcal Disease Cases by Age Group and Site from Active Bacterial Core surveillance

CDC monitors invasive bacterial infections that cause bloodstream infections, sepsis, and meningitis in persons living in the community through Active Bacterial Core surveillance (ABCs). ABCs conducts laboratory- and population-based surveillance for invasive pneumococcal disease (IPD). ABCs serotype data are used to measure the impact of vaccine use in the United States on vaccine-type IPD. This table reports IPD case counts in the ABCs catchment area by serotype for years 1998 through 2024. Cases are grouped into the following mutually exclusive age groups: age <2 years old, age 2–4 years old, age 5–17 years old, age 18–49 years old, age 50–64 years old, and age ≥65 years old. Cases are reported by ABCs surveillance site (noted as the 2-letter state abbreviation). Combined data for all ABCs sites are labeled as “All_Sites”. [ABCs methods] and [surveillance areas] reporting IPD cases have changed over time. Given these changes, trends in serotype distribution by year, age group, and site should be interpreted with caution. Analyze and visualize data using the [ABCs Bact Facts Interactive Data Dashboard].
2020-2021 Nationwide Blood Donor Seroprevalence Survey Combined Infection- and Vaccination-Induced Seroprevalence Estimates

CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Combined seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection, COVID-19 vaccination, or both. It estimates the proportion of the population with some presumed protection against infection with the virus that causes COVID-19. The term “combined seroprevalence” refers to the combined infection- and vaccination-induced SARS-CoV-2 seroprevalences. This is the population that has anti-S antibodies, regardless of the presence of anti-N antibodies. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html
2020-2021 Nationwide Blood Donor Seroprevalence Survey Infection-Induced Seroprevalence Estimates

CDC is collaborating with the National Institutes of Health (NIH), the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), Westat Inc., and numerous blood collection organizations across the United States to conduct a nationwide COVID-19 seroprevalence survey of blood donors. This is the largest nationwide COVID-19 seroprevalence survey to date. De-identified blood samples are tested for antibodies to SARS-CoV-2 to better understand the percentage of people in the United States who have antibodies against SARS-CoV-2 (the virus that causes COVID-19) and to track how this percentage changes over time. Both SARS-CoV-2 infection and COVID-19 vaccines currently used in the United States result in production of anti-spike (anti-S) antibodies but only infection results in production of anti-nucleocapsid (anti-N) antibodies. Infection-induced seroprevalence estimates the proportion of the population with evidence of previous SARS-CoV-2 infection and refers to the prevalence of the population with both anti-S and anti-N antibodies. This link connects to a webpage that displays the data from the Nationwide Blood Donor Seroprevalence Survey. It offers an interactive visualization available at https://covid.cdc.gov/covid-data-tracker/#nationwide-blood-donor-seroprevalence Additional information is available at: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/blood-bank-serosurvey.html